| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Resistant Epilepsy | 13 | 2025 | 226 | 3.700 |
Why?
|
| Laser Therapy | 10 | 2024 | 226 | 3.550 |
Why?
|
| Epilepsy | 20 | 2024 | 843 | 2.680 |
Why?
|
| Hypothalamic Diseases | 6 | 2022 | 38 | 2.480 |
Why?
|
| Hamartoma | 6 | 2022 | 50 | 2.480 |
Why?
|
| Rhizotomy | 3 | 2024 | 17 | 2.170 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2026 | 3557 | 2.100 |
Why?
|
| Cerebral Palsy | 3 | 2024 | 80 | 1.990 |
Why?
|
| Seizures | 9 | 2025 | 850 | 1.850 |
Why?
|
| Muscle Spasticity | 3 | 2024 | 55 | 1.620 |
Why?
|
| Hemispherectomy | 4 | 2024 | 26 | 1.480 |
Why?
|
| Electroencephalography | 11 | 2025 | 841 | 1.400 |
Why?
|
| Stereotaxic Techniques | 6 | 2025 | 75 | 1.180 |
Why?
|
| Electrocorticography | 4 | 2024 | 63 | 1.060 |
Why?
|
| Neurosurgical Procedures | 9 | 2024 | 299 | 1.050 |
Why?
|
| Neural Pathways | 2 | 2019 | 260 | 1.030 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 1 | 2026 | 21 | 0.970 |
Why?
|
| Dystonia | 2 | 2019 | 163 | 0.930 |
Why?
|
| Epilepsies, Partial | 5 | 2020 | 86 | 0.910 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2026 | 110 | 0.890 |
Why?
|
| Child | 55 | 2026 | 25015 | 0.840 |
Why?
|
| Child, Preschool | 36 | 2026 | 14316 | 0.840 |
Why?
|
| Genetic Therapy | 1 | 2026 | 679 | 0.710 |
Why?
|
| Adolescent | 38 | 2026 | 19904 | 0.700 |
Why?
|
| Treatment Outcome | 29 | 2026 | 12334 | 0.690 |
Why?
|
| Rest | 2 | 2019 | 64 | 0.680 |
Why?
|
| Brain | 9 | 2024 | 3016 | 0.650 |
Why?
|
| Spinal Fusion | 10 | 2012 | 110 | 0.640 |
Why?
|
| Electrodes, Implanted | 5 | 2025 | 172 | 0.620 |
Why?
|
| Tumor Burden | 1 | 2020 | 228 | 0.620 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2018 | 2 | 0.600 |
Why?
|
| Brain Mapping | 4 | 2024 | 383 | 0.570 |
Why?
|
| Infant | 27 | 2026 | 12758 | 0.570 |
Why?
|
| Male | 56 | 2026 | 61966 | 0.550 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2017 | 7 | 0.550 |
Why?
|
| Humans | 89 | 2026 | 125613 | 0.550 |
Why?
|
| Tuberous Sclerosis | 4 | 2023 | 121 | 0.550 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 51 | 0.540 |
Why?
|
| Deep Brain Stimulation | 4 | 2024 | 409 | 0.530 |
Why?
|
| Poloxamer | 3 | 2007 | 14 | 0.510 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2019 | 189 | 0.500 |
Why?
|
| Female | 55 | 2026 | 67790 | 0.490 |
Why?
|
| Bone Screws | 6 | 2011 | 52 | 0.460 |
Why?
|
| Retrospective Studies | 27 | 2025 | 16725 | 0.460 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2014 | 15 | 0.440 |
Why?
|
| Anesthetics, Combined | 1 | 2014 | 7 | 0.440 |
Why?
|
| Microelectrodes | 1 | 2014 | 41 | 0.440 |
Why?
|
| Neurophysiological Monitoring | 1 | 2014 | 35 | 0.420 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2022 | 56 | 0.420 |
Why?
|
| Hydrocephalus | 4 | 2011 | 276 | 0.400 |
Why?
|
| Neuroendoscopy | 4 | 2011 | 31 | 0.400 |
Why?
|
| Dystonic Disorders | 1 | 2014 | 95 | 0.400 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2012 | 93 | 0.400 |
Why?
|
| Neural Tube Defects | 3 | 2019 | 362 | 0.380 |
Why?
|
| Radiosurgery | 1 | 2013 | 107 | 0.380 |
Why?
|
| Young Adult | 14 | 2024 | 9556 | 0.380 |
Why?
|
| Hippocampus | 4 | 2024 | 772 | 0.370 |
Why?
|
| Anesthesia | 1 | 2014 | 209 | 0.360 |
Why?
|
| Follow-Up Studies | 7 | 2026 | 5079 | 0.360 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2020 | 587 | 0.360 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 2168 | 0.350 |
Why?
|
| Kyphosis | 5 | 2012 | 22 | 0.350 |
Why?
|
| Surface-Active Agents | 3 | 2007 | 29 | 0.340 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 277 | 0.340 |
Why?
|
| Cervical Vertebrae | 5 | 2012 | 106 | 0.320 |
Why?
|
| Postoperative Complications | 11 | 2019 | 2974 | 0.300 |
Why?
|
| Spine | 5 | 2012 | 136 | 0.290 |
Why?
|
| Quinolinic Acid | 2 | 2004 | 10 | 0.280 |
Why?
|
| Cohort Studies | 6 | 2025 | 4878 | 0.260 |
Why?
|
| Neurosurgery | 2 | 2022 | 73 | 0.260 |
Why?
|
| Lumbar Vertebrae | 3 | 2011 | 103 | 0.250 |
Why?
|
| Homovanillic Acid | 1 | 2026 | 30 | 0.250 |
Why?
|
| Neuroprotective Agents | 3 | 2019 | 155 | 0.240 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2005 | 11 | 0.240 |
Why?
|
| Magnetoencephalography | 1 | 2025 | 46 | 0.230 |
Why?
|
| Spinal Neoplasms | 3 | 2011 | 53 | 0.230 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 265 | 0.230 |
Why?
|
| Thoracic Vertebrae | 5 | 2012 | 66 | 0.220 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2021 | 0.220 |
Why?
|
| Necrosis | 1 | 2004 | 196 | 0.210 |
Why?
|
| Catheterization | 1 | 2005 | 231 | 0.210 |
Why?
|
| Injections, Spinal | 2 | 2019 | 130 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2012 | 1973 | 0.200 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2023 | 63 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2024 | 221 | 0.190 |
Why?
|
| Muscle Relaxants, Central | 2 | 2019 | 37 | 0.190 |
Why?
|
| Baclofen | 2 | 2019 | 43 | 0.190 |
Why?
|
| Genetic Vectors | 1 | 2026 | 890 | 0.190 |
Why?
|
| Functional Laterality | 2 | 2020 | 173 | 0.180 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2023 | 242 | 0.180 |
Why?
|
| Quadriplegia | 1 | 2021 | 34 | 0.170 |
Why?
|
| Intracranial Aneurysm | 2 | 2012 | 77 | 0.160 |
Why?
|
| Reoperation | 4 | 2018 | 788 | 0.160 |
Why?
|
| Ependymoma | 1 | 2021 | 138 | 0.160 |
Why?
|
| Infratentorial Neoplasms | 2 | 2010 | 36 | 0.160 |
Why?
|
| Microsurgery | 2 | 2011 | 63 | 0.160 |
Why?
|
| Criminal Psychology | 1 | 1999 | 3 | 0.160 |
Why?
|
| Dengue Vaccines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Day Care, Medical | 1 | 1999 | 10 | 0.160 |
Why?
|
| Residential Treatment | 1 | 1999 | 13 | 0.160 |
Why?
|
| Social Behavior Disorders | 1 | 1999 | 11 | 0.160 |
Why?
|
| Psychology, Adolescent | 1 | 1999 | 34 | 0.150 |
Why?
|
| Astrocytoma | 2 | 2010 | 96 | 0.150 |
Why?
|
| Crime | 1 | 1999 | 26 | 0.150 |
Why?
|
| Skull Fractures | 1 | 1999 | 46 | 0.150 |
Why?
|
| Ventriculoperitoneal Shunt | 2 | 2010 | 56 | 0.150 |
Why?
|
| MPTP Poisoning | 1 | 2019 | 3 | 0.150 |
Why?
|
| Juvenile Delinquency | 1 | 1999 | 25 | 0.150 |
Why?
|
| Substantia Nigra | 1 | 2019 | 35 | 0.150 |
Why?
|
| Hematoma | 1 | 1999 | 84 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2004 | 690 | 0.150 |
Why?
|
| Craniotomy | 2 | 2017 | 99 | 0.150 |
Why?
|
| Ghrelin | 1 | 2019 | 57 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 229 | 0.150 |
Why?
|
| Spasms, Infantile | 1 | 2020 | 163 | 0.150 |
Why?
|
| Dopaminergic Neurons | 1 | 2019 | 49 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2021 | 312 | 0.150 |
Why?
|
| Embolization, Therapeutic | 2 | 2012 | 211 | 0.150 |
Why?
|
| Meningomyelocele | 2 | 2012 | 249 | 0.150 |
Why?
|
| Cerebral Cortex | 3 | 2018 | 442 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2019 | 6162 | 0.140 |
Why?
|
| Joint Instability | 2 | 2009 | 57 | 0.140 |
Why?
|
| Scoliosis | 4 | 2012 | 136 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2019 | 322 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2021 | 390 | 0.140 |
Why?
|
| Electrocoagulation | 1 | 2018 | 32 | 0.140 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2018 | 36 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 1217 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 375 | 0.130 |
Why?
|
| Neurons | 3 | 2010 | 1908 | 0.130 |
Why?
|
| Inflammation | 1 | 2004 | 1428 | 0.130 |
Why?
|
| Language | 1 | 2018 | 204 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 29 | 0.120 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 391 | 0.120 |
Why?
|
| Radiography | 7 | 2012 | 745 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 121 | 0.120 |
Why?
|
| Ankyrins | 1 | 2016 | 92 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2856 | 0.120 |
Why?
|
| Malformations of Cortical Development, Group I | 1 | 2015 | 3 | 0.120 |
Why?
|
| Fornix, Brain | 1 | 2015 | 20 | 0.120 |
Why?
|
| Laminectomy | 2 | 2019 | 23 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2019 | 742 | 0.110 |
Why?
|
| Emergency Medical Services | 2 | 2010 | 398 | 0.110 |
Why?
|
| Encephalitis | 1 | 2016 | 117 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 134 | 0.110 |
Why?
|
| Perioperative Care | 1 | 2017 | 206 | 0.110 |
Why?
|
| Nicardipine | 1 | 2014 | 13 | 0.110 |
Why?
|
| Anesthetics, Dissociative | 1 | 2014 | 18 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2007 | 1132 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 150 | 0.110 |
Why?
|
| Oxygen | 1 | 2017 | 544 | 0.110 |
Why?
|
| Dexmedetomidine | 1 | 2014 | 47 | 0.100 |
Why?
|
| Wakefulness | 1 | 2014 | 90 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 2 | 2011 | 127 | 0.100 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2011 | 55 | 0.100 |
Why?
|
| Vasospasm, Intracranial | 2 | 2004 | 18 | 0.100 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 354 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 412 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2014 | 130 | 0.100 |
Why?
|
| Rett Syndrome | 1 | 2015 | 216 | 0.100 |
Why?
|
| Neuralgia | 1 | 2013 | 49 | 0.100 |
Why?
|
| Internal Fixators | 1 | 2012 | 12 | 0.100 |
Why?
|
| Arthrodesis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Piperidines | 1 | 2014 | 214 | 0.100 |
Why?
|
| Aneurysm, Ruptured | 1 | 2012 | 30 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2022 | 1163 | 0.090 |
Why?
|
| Memory | 1 | 2015 | 347 | 0.090 |
Why?
|
| Tuberculosis, Spinal | 1 | 2012 | 9 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2012 | 69 | 0.090 |
Why?
|
| Sympathectomy | 1 | 2011 | 8 | 0.090 |
Why?
|
| Cranial Sutures | 1 | 2012 | 34 | 0.090 |
Why?
|
| Osteoblastoma | 1 | 2011 | 3 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 225 | 0.090 |
Why?
|
| Amenorrhea | 1 | 2011 | 19 | 0.090 |
Why?
|
| Posters as Topic | 1 | 2011 | 7 | 0.090 |
Why?
|
| Corpus Callosum | 1 | 2012 | 101 | 0.090 |
Why?
|
| Cauda Equina | 1 | 2011 | 7 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2011 | 43 | 0.090 |
Why?
|
| Publications | 1 | 2011 | 35 | 0.090 |
Why?
|
| Ventriculostomy | 1 | 2011 | 45 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 389 | 0.090 |
Why?
|
| Diskectomy | 1 | 2011 | 12 | 0.090 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2011 | 19 | 0.090 |
Why?
|
| Peer Review, Research | 1 | 2011 | 44 | 0.090 |
Why?
|
| Fracture Fixation | 1 | 2011 | 28 | 0.090 |
Why?
|
| Sleep | 1 | 2014 | 350 | 0.090 |
Why?
|
| Rats | 4 | 2007 | 3388 | 0.090 |
Why?
|
| Evoked Potentials, Motor | 1 | 2011 | 34 | 0.090 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cisterna Magna | 3 | 2007 | 4 | 0.090 |
Why?
|
| Long QT Syndrome | 1 | 2011 | 83 | 0.080 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2010 | 18 | 0.080 |
Why?
|
| Ketamine | 1 | 2014 | 222 | 0.080 |
Why?
|
| Vein of Galen Malformations | 1 | 2010 | 16 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2010 | 23 | 0.080 |
Why?
|
| Malformations of Cortical Development | 1 | 2010 | 54 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2011 | 174 | 0.080 |
Why?
|
| Respiratory Tract Fistula | 1 | 2010 | 17 | 0.080 |
Why?
|
| Polyesters | 1 | 2010 | 34 | 0.080 |
Why?
|
| Spinal Cord | 3 | 2023 | 243 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2011 | 130 | 0.080 |
Why?
|
| Pleural Diseases | 1 | 2010 | 32 | 0.080 |
Why?
|
| Critical Pathways | 1 | 2010 | 68 | 0.080 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2010 | 123 | 0.080 |
Why?
|
| Prosthesis Failure | 1 | 2010 | 140 | 0.080 |
Why?
|
| Craniosynostoses | 1 | 2012 | 138 | 0.080 |
Why?
|
| Hematoma, Epidural, Spinal | 1 | 2009 | 7 | 0.080 |
Why?
|
| Ophthalmoplegia | 1 | 2009 | 36 | 0.080 |
Why?
|
| Thoracotomy | 1 | 2010 | 102 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 155 | 0.080 |
Why?
|
| Neuroendoscopes | 1 | 2009 | 2 | 0.080 |
Why?
|
| Chondroma | 1 | 2009 | 5 | 0.080 |
Why?
|
| Choroid Plexus | 1 | 2009 | 22 | 0.080 |
Why?
|
| Atlanto-Axial Joint | 1 | 2009 | 21 | 0.080 |
Why?
|
| Cervical Atlas | 1 | 2009 | 6 | 0.080 |
Why?
|
| Rhabdoid Tumor | 1 | 2009 | 47 | 0.070 |
Why?
|
| Hydrothorax | 1 | 2008 | 11 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2009 | 46 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2012 | 62 | 0.070 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2009 | 33 | 0.070 |
Why?
|
| Adult | 8 | 2023 | 30189 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 2507 | 0.070 |
Why?
|
| Periosteum | 1 | 2009 | 29 | 0.070 |
Why?
|
| Corpus Striatum | 2 | 2007 | 90 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 446 | 0.070 |
Why?
|
| Geography | 1 | 2008 | 119 | 0.070 |
Why?
|
| Pneumothorax | 1 | 2008 | 81 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2019 | 1166 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1289 | 0.070 |
Why?
|
| Cerebral Hemorrhage, Traumatic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Animals | 10 | 2019 | 33094 | 0.070 |
Why?
|
| Patient Transfer | 1 | 2008 | 107 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 2010 | 314 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 1403 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 309 | 0.060 |
Why?
|
| Hospitalization | 1 | 2014 | 1804 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 380 | 0.060 |
Why?
|
| Neuronavigation | 1 | 2005 | 8 | 0.060 |
Why?
|
| Thalamic Nuclei | 1 | 2024 | 18 | 0.050 |
Why?
|
| Length of Stay | 3 | 2019 | 1309 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 1028 | 0.050 |
Why?
|
| Magnesium Sulfate | 1 | 2004 | 51 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2007 | 752 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2024 | 79 | 0.050 |
Why?
|
| Age Factors | 4 | 2011 | 2757 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 128 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 1119 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 19 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2022 | 45 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2002 | 36 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 145 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 2007 | 0.050 |
Why?
|
| Middle Aged | 5 | 2018 | 27263 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 4419 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 21 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 78 | 0.040 |
Why?
|
| Artifacts | 1 | 2022 | 105 | 0.040 |
Why?
|
| Workload | 1 | 2022 | 147 | 0.040 |
Why?
|
| Electrodes | 1 | 2020 | 84 | 0.040 |
Why?
|
| Macrophages | 1 | 2004 | 643 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 132 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 410 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 1999 | 18 | 0.040 |
Why?
|
| Utah | 1 | 1999 | 82 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 122 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 1999 | 194 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 406 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 134 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 108 | 0.040 |
Why?
|
| Family Therapy | 1 | 1999 | 34 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2019 | 173 | 0.040 |
Why?
|
| Receptors, Ghrelin | 1 | 2019 | 29 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 1999 | 56 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2019 | 65 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 193 | 0.040 |
Why?
|
| Dengue Virus | 1 | 2019 | 131 | 0.040 |
Why?
|
| Dengue | 1 | 2019 | 120 | 0.040 |
Why?
|
| Periodicity | 1 | 2018 | 44 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 168 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 97 | 0.030 |
Why?
|
| Apoptosis | 1 | 2004 | 1795 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 503 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 49 | 0.030 |
Why?
|
| Time Factors | 3 | 2010 | 6020 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2018 | 128 | 0.030 |
Why?
|
| Data Collection | 1 | 1999 | 368 | 0.030 |
Why?
|
| Obesity | 1 | 2009 | 2326 | 0.030 |
Why?
|
| Checklist | 1 | 2018 | 96 | 0.030 |
Why?
|
| Public Health | 1 | 2019 | 267 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 224 | 0.030 |
Why?
|
| Parvalbumins | 1 | 2016 | 36 | 0.030 |
Why?
|
| Action Potentials | 1 | 2019 | 459 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 259 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 17528 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 217 | 0.030 |
Why?
|
| Software | 1 | 2021 | 709 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Spatial Learning | 1 | 2015 | 16 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 399 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 144 | 0.030 |
Why?
|
| Interneurons | 1 | 2016 | 137 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 105 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1219 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 295 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 1995 | 148 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 579 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 948 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1774 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 603 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 752 | 0.030 |
Why?
|
| Fear | 1 | 2015 | 199 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 295 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2015 | 206 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 1145 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 1129 | 0.030 |
Why?
|
| Macaca fascicularis | 2 | 2004 | 81 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 471 | 0.020 |
Why?
|
| Spondylitis | 1 | 2012 | 8 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2005 | 8362 | 0.020 |
Why?
|
| Ischemia | 1 | 1995 | 347 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2012 | 48 | 0.020 |
Why?
|
| Head Protective Devices | 1 | 2012 | 23 | 0.020 |
Why?
|
| Back Pain | 1 | 2012 | 28 | 0.020 |
Why?
|
| Ganglia, Sympathetic | 1 | 2011 | 8 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1599 | 0.020 |
Why?
|
| Stellate Ganglion | 1 | 2011 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2012 | 157 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 673 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1534 | 0.020 |
Why?
|
| Atenolol | 1 | 2011 | 43 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1596 | 0.020 |
Why?
|
| Third Ventricle | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2015 | 542 | 0.020 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2011 | 6 | 0.020 |
Why?
|
| Syncope | 1 | 2011 | 42 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2316 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1995 | 358 | 0.020 |
Why?
|
| Pyramidal Tracts | 1 | 2011 | 36 | 0.020 |
Why?
|
| Gait | 1 | 2012 | 142 | 0.020 |
Why?
|
| Fentanyl | 1 | 2011 | 53 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 565 | 0.020 |
Why?
|
| Insulin | 1 | 1995 | 1132 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 671 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2011 | 238 | 0.020 |
Why?
|
| Skull | 1 | 2012 | 147 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2010 | 49 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2010 | 87 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 10 | 0.020 |
Why?
|
| Ganglioneuroma | 1 | 2010 | 17 | 0.020 |
Why?
|
| Safety | 1 | 2011 | 210 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 781 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 210 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2011 | 121 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2010 | 38 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2010 | 114 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3295 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 106 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 303 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1715 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 354 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2010 | 106 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 280 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2011 | 208 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 196 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 145 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2009 | 92 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 421 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2008 | 16 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 192 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 146 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2010 | 196 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 782 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1348 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2742 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1038 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2011 | 721 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 1292 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1228 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2007 | 55 | 0.020 |
Why?
|
| Synaptic Membranes | 1 | 2007 | 21 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 581 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2007 | 89 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1736 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3248 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1218 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 775 | 0.010 |
Why?
|
| Risk Factors | 2 | 2010 | 10346 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 1471 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 734 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 824 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 1178 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 2041 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 1521 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1632 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2002 | 96 | 0.010 |
Why?
|
| Injections | 1 | 2002 | 134 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 2002 | 89 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 78 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 334 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 4668 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 307 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3414 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11141 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 197 | 0.010 |
Why?
|
| Temperature | 1 | 1995 | 284 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 1089 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1995 | 500 | 0.010 |
Why?
|